NCT06168227View on ClinicalTrials.gov

A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

CompletedOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

September 30, 2023

Conditions

Breast Cancer

Interventions

DRUG

Disitamb Vedotin

RC48-ADC based therapy

Trial Locations (1)

210000

Jiangsu Provincial People's Hospital, Nanjing

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06168227 - A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter